公开(公告)号：US09931405B2

公开(公告)日：2018-04-03

申请号：US14611578

申请日：2015-02-02

申请人： LUPIN LIMITED

发明人： Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

IPC分类号： A61K9/14 ,  A61K47/44 ,  A61K38/12 ,  A61K31/196 ,  A61K31/785 ,  A61K31/197 ,  A61K31/4402 ,  A61K47/38 ,  A61K47/34 ,  A61K47/32 ,  A61K9/00 ,  A61K9/20 ,  A61K9/24 ,  A61K31/437 ,  A61K31/606 ,  A61K31/635 ,  A61K31/655 ,  A61K9/16

CPC分类号： A61K47/44 ,  A61K9/0065 ,  A61K9/0095 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/196 ,  A61K31/197 ,  A61K31/437 ,  A61K31/4402 ,  A61K31/606 ,  A61K31/635 ,  A61K31/655 ,  A61K31/785 ,  A61K38/12 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.